These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 29151192)

  • 21. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Rapid Antidepressant and Antisuicidal Effects of Intramuscular Ketamine, Oral Ketamine, and Electroconvulsive Therapy in Patients With Major Depressive Disorder: A Pilot Study.
    Kheirabadi D; Kheirabadi GR; Mirlohi Z; Tarrahi MJ; Norbaksh A
    J Clin Psychopharmacol; 2020; 40(6):588-593. PubMed ID: 33060432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychiatric Outcomes of Patients With Severe Agitation Following Administration of Prehospital Ketamine.
    Lebin JA; Akhavan AR; Hippe DS; Gittinger MH; Pasic J; McCoy AM; Vrablik MC
    Acad Emerg Med; 2019 Aug; 26(8):889-896. PubMed ID: 30873690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
    Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
    Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions.
    Riva-Posse P; Reiff CM; Edwards JA; Job GP; Galendez GC; Garlow SJ; Saah TC; Dunlop BW; McDonald WM
    J Affect Disord; 2018 Aug; 236():291-297. PubMed ID: 29525051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effectiveness of ketamine in depressed patients resistant to ECT or rTMS therapy].
    Gosek P; Chojnacka M; Bieńkowski P; Swiecicki Ł
    Psychiatr Pol; 2014; 48(1):49-58. PubMed ID: 24946434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New use for an old drug: oral ketamine for treatment-resistant depression.
    Swiatek KM; Jordan K; Coffman J
    BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27489070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Low-Dose Ketamine on the Antidepressant Efficacy and Suicidal Ideations in Patients Undergoing Electroconvulsive Therapy.
    Chen Q; Dong J; Luo J; Ren L; Min S; Hao X; Luo Q; Chen J; Li X
    J ECT; 2020 Mar; 36(1):25-30. PubMed ID: 31913927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.
    Glue P; Medlicott NJ; Harland S; Neehoff S; Anderson-Fahey B; Le Nedelec M; Gray A; McNaughton N
    J Psychopharmacol; 2017 Oct; 31(10):1302-1305. PubMed ID: 28441895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
    Wajs E; Aluisio L; Holder R; Daly EJ; Lane R; Lim P; George JE; Morrison RL; Sanacora G; Young AH; Kasper S; Sulaiman AH; Li CT; Paik JW; Manji H; Hough D; Grunfeld J; Jeon HJ; Wilkinson ST; Drevets WC; Singh JB
    J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32316080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral Ketamine in Treatment-Resistant Depression: A Clinical Effectiveness Case Series.
    Al Shirawi MI; Kennedy SH; Ho KT; Byrne R; Downar J
    J Clin Psychopharmacol; 2017 Aug; 37(4):464-467. PubMed ID: 28514237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
    Singh JB; Fedgchin M; Daly EJ; Drevets WC
    Adv Pharmacol; 2020; 89():237-259. PubMed ID: 32616208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness.
    Thomas RK; Baker G; Lind J; Dursun S
    J Psychopharmacol; 2018 Oct; 32(10):1110-1117. PubMed ID: 30182797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety.
    Szarmach J; Cubała WJ; Włodarczyk A; Wiglusz MS
    Psychiatr Danub; 2019 Sep; 31(Suppl 3):585-590. PubMed ID: 31488795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: A report of two cases.
    Bartova L; Vogl SE; Stamenkovic M; Praschak-Rieder N; Naderi-Heiden A; Kasper S; Willeit M
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):2183-4. PubMed ID: 26302763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time until relapse after augmentation with single-dose ketamine in treatment-resistant depression.
    Pérez-Esparza R; Corona T; Ruiz-García RG; Oñate-Cadena N; de la Fuente-Sandoval C; Ramírez-Bermúdez J
    Psychiatry Clin Neurosci; 2018 Aug; 72(8):623. PubMed ID: 29744959
    [No Abstract]   [Full Text] [Related]  

  • 37. Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.
    Lenze EJ; Farber NB; Kharasch E; Schweiger J; Yingling M; Olney J; Newcomer JW
    World J Biol Psychiatry; 2016 Apr; 17(3):230-8. PubMed ID: 26919405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ketamine for treatment-resistant depression: recent developments and clinical applications.
    Schwartz J; Murrough JW; Iosifescu DV
    Evid Based Ment Health; 2016 May; 19(2):35-8. PubMed ID: 27053196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral Ketamine for Depression: A Systematic Review.
    Rosenblat JD; Carvalho AF; Li M; Lee Y; Subramanieapillai M; McIntyre RS
    J Clin Psychiatry; 2019 Apr; 80(3):. PubMed ID: 30995364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis.
    Włodarczyk A; Cubała WJ
    Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32050466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.